NCT05628376

TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 600 (estimated)
• Sponsor: University College, London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.

Detailed description

TRACERx EVO is a programme of work linked to an observational cohort study that consists of early and late-stage lung cancer and pleural mesothelioma. Participants will receive anti-cancer therapies (systemic therapies, radiotherapy and surgery, as per local and national guidelines). This study involves collecting a large amount of data, covering demographic and clinical characteristics, data throughout their follow up from the time of baseline/surgery, genomics and all other laboratory results using their blood, tissue, urine, saliva and stool samples. Data would also be retrieved from participant medical records. As such, there will be a wide range of analyses

Conditions

• Lung Cancer, Non-small Cell
• Small Cell Lung Cancer
• Pleural Mesothelioma

Timeline

• Start date: 2023-12-04
• Primary completion: 2030-12-01
• Completion: 2034-06-01
• First posted: 2022-11-28
• Last updated: 2025-04-02

Locations

1 site across 1 country: United Kingdom